Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).
about
Tyrosine phosphorylation enhances RAD52-mediated annealing by modulating its DNA binding.Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemiaMolecular cloning of Ian4: a BCR/ABL-induced gene that encodes an outer membrane mitochondrial protein with GTP-binding activityTyrosine phosphorylation of BCR by FPS/FES protein-tyrosine kinases induces association of BCR with GRB-2/SOSCombating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaThe Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesisInteractions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cellsMolecular mechanisms of cancer.Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells.The management of patients with leukaemia: the role of cytogenetics in this molecular era.Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemiaUnexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemiaRegulation of hTERT by BCR-ABL at multiple levels in K562 cells.Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway.Bone marrow transplant in Ph+ ALL patients.Imatinib mesylate in the treatment of chronic myeloid leukaemia.The polymerase chain reaction: its use in the molecular characterization and diagnosis of cancers.Cytogenetic abnormalities in childhood acute lymphoblastic leukemia correlates with clinical features and treatment outcome.Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant.Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice.BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines.The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc.Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures.Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteinsNovel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.Leukemia initiated by hemopoietic stem cells expressing the v-abl oncogene.Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
P2860
Q24318110-5A8F2D96-7849-4F2D-A027-7C3DAC39273DQ24599829-5290D607-6FEF-4188-BDA7-E509B873D839Q24613207-6A67E0C7-B79C-4FB2-8A80-61AE0A75FD19Q24646851-2123FB5D-FBD1-4E84-8DEE-6CC1A81C8955Q26851166-D3B3868C-FC35-4181-9590-F12AFEAF9E03Q30165112-3E0ECA33-ED82-431A-B35D-F256AF6F1D3FQ30175784-5C54DA7C-1924-4CC9-9858-123478865A5AQ30175971-AC9F7528-588A-4A77-B033-0F93B722D9C3Q30424785-3683D1B9-3792-42CC-80B5-DB531189CBACQ30498610-9C837773-4040-43E4-8CFF-B9D53D6B9EC6Q33602552-09F81272-AB00-4B40-BEF0-BAD0C9DF864FQ33636924-4B25A74A-439A-43E9-B02E-7A11CE2F519CQ33796384-E840D448-7D4C-4394-93B2-4642E735BED2Q33826389-AF6223AF-1E45-49A4-8652-BFD218BA7B19Q33867942-B7C452AF-3B9D-490A-ABB4-3AF2A2433B9BQ33867956-12D8EE92-365D-40EE-A961-F94A6E1F5D83Q34094028-AE4D6255-D651-4A21-8DB0-C9CAFAAE2D07Q34250223-CE5C42A9-BAF5-4F67-ADAF-12EDF68560E1Q34281241-7E726E4B-ECCA-4724-B1EE-383D1D6A7E17Q35037415-FB9D52DA-FE25-4C62-B54D-78E656965576Q35096615-8C4E3AF3-E9E2-48AA-B449-1F7CBF02C986Q35106125-2A38DFB6-B78B-4AAB-A4DA-85FEA66807A4Q35143966-EFA17515-973E-4B9E-A389-896442CDB610Q35367235-D18C7C7A-4902-47CB-922C-AD07EC6206D9Q35664675-19DAD15B-18A5-4E49-8722-1EC0291AE4D1Q35712192-FC3CFA4C-12F6-4E47-88F6-478AA700446FQ36140620-B4DBD266-C41B-4417-B532-69B9C4B0A6FBQ36323612-C16258E9-90D0-43E7-B134-4CE79A6234D9Q36363202-C60FCFF4-4FEE-4F76-BD4A-7BF105CA2CF0Q36401150-2D6C1B96-26D2-49AC-BEDC-7469F85163F0Q36634604-334A8943-F56C-4EBD-A434-8D8D4FB1BE67Q36653547-AFA7D8FA-D6AD-408A-9810-C1DEC35C70A8Q36687654-7E6BA8B2-64DE-41D0-8F1B-D27766F6D76AQ36768150-C9C58B99-2ED0-481E-AAF5-9F3BCFEF377FQ36776463-F10BA84E-BC2C-49BD-8C76-139C3123C2F1Q36846338-0E384E5B-670B-43EF-B9F9-A9DFD12C0662Q36959846-B66A7383-C171-43E9-91B1-47139A438D05Q37248354-3B231CC0-9675-45A3-A0F4-B9378A2EFADFQ37409990-EF0EC38D-F85D-40AF-A536-29099C740C36Q37696776-73DAA407-B791-4334-BEEA-52D91D38D93B
P2860
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
Expression of a distinctive BC ...... te lymphocytic leukemia (ALL).
@en
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia
@nl
type
label
Expression of a distinctive BC ...... te lymphocytic leukemia (ALL).
@en
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia
@nl
prefLabel
Expression of a distinctive BC ...... te lymphocytic leukemia (ALL).
@en
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia
@nl
P2093
P356
P1433
P1476
Expression of a distinctive BC ...... te lymphocytic leukemia (ALL).
@en
P2093
Ben-Neriah Y
McLaughlin J
Pendergast AM
P304
P356
10.1126/SCIENCE.3422516
P407
P433
P577
1988-02-01T00:00:00Z